For the millions of people worldwide living with end-stage renal disease (ESRD), dialysis is not merely a medical procedure — it is a lifeline. While hemodialysis remains the most widely used form of kidney replacement therapy globally, peritoneal dialysis (PD) offers a flexible, home-based alternative that continues to demonstrate meaningful clinical and quality-of-life advantages for carefully selected patients. Yet the long-term success of peritoneal dialysis depends on two interconnected pillars that are often underappreciated outside specialist circles: ensuring adequate dialysis delivery and preserving the health of the peritoneal membrane itself.
The International Society of Nephrology, alongside its global partners, has long championed the advancement of best practices in peritoneal dialysis management. This article provides a comprehensive, accessible overview of what peritoneal dialysis adequacy means, why the peritoneal membrane must be protected, and what the current evidence tells us about achieving the best outcomes for patients on this therapy.
Understanding Peritoneal Dialysis: The Basics
The peritoneum is a thin, semipermeable membrane that lines the abdominal cavity and surrounds the internal organs. In peritoneal dialysis, this biological membrane is used as a natural filter. A sterile dialysis solution — called dialysate — is infused into the peritoneal cavity through a surgically placed catheter. Waste products and excess fluid from the blood diffuse across the peritoneal membrane into the dialysate, which is then drained and discarded. This process, called a “dwell,” is repeated multiple times each day or overnight, depending on the PD regimen.
There are two principal forms of peritoneal dialysis:
- Continuous Ambulatory Peritoneal Dialysis (CAPD): The patient manually performs exchanges several times per day, with the dialysate dwelling in the abdomen for several hours between exchanges.
- Automated Peritoneal Dialysis (APD): A machine (cycler) performs the exchanges automatically, typically overnight while the patient sleeps.
Both modalities rely on the same fundamental principle — using the peritoneum as a dialysis membrane — but differ in scheduling, volume, and patient burden. Regardless of the approach, two critical factors determine long-term success: how much dialysis the patient is actually receiving (adequacy), and whether the peritoneal membrane is remaining healthy enough to continue performing its filtering role (membrane preservation).
What Is Dialysis Adequacy and Why Does It Matter?
The Concept of Kt/V Urea
Dialysis adequacy is a measure of how effectively waste products are being removed from the body. The primary metric used to assess adequacy in peritoneal dialysis is Kt/V urea — a dimensionless ratio that combines three variables: K (the clearance of urea by the dialysis), t (the time over which dialysis is delivered), and V (the volume of distribution of urea in the patient’s body, approximated as total body water).
In plain terms, Kt/V tells us how many times a patient’s body water has been “cleaned” of urea over a given period. Because urea is a small, freely diffusible molecule generated by protein metabolism, it serves as a surrogate marker for the removal of other uremic toxins. A higher Kt/V generally indicates more thorough dialysis.
Current Clinical Targets
The KDIGO 2022 Clinical Practice Guideline for Peritoneal Dialysis Adequacy — developed with the support of the International Society of Nephrology — recommends a minimum total weekly Kt/V urea of 1.7 for anuric patients (those who no longer produce meaningful amounts of urine). This threshold represents a clinically validated minimum below which outcomes begin to deteriorate significantly.
Importantly, total Kt/V in peritoneal dialysis has two components:
- Peritoneal Kt/V: The clearance provided by the PD process itself — determined by the volume and frequency of exchanges, dwell time, and the transport characteristics of the patient’s peritoneal membrane.
- Residual renal Kt/V: The clearance still contributed by the patient’s own kidneys, even in advanced chronic kidney disease (CKD). This residual kidney function (RKF) can be substantial, particularly early in a patient’s time on dialysis.
The Critical Role of Residual Kidney Function
One of the most important findings to reshape clinical thinking about peritoneal dialysis adequacy was published by Bargman and colleagues in the Journal of the American Society of Nephrology in 2001, using data from the landmark CANUSA study. Their analysis demonstrated that residual renal clearance was a considerably more powerful predictor of survival on peritoneal dialysis than peritoneal clearance alone — a finding that has had profound implications for clinical practice.
This discovery reframed how clinicians approach the early period of dialysis initiation. Protecting residual kidney function is now understood to be one of the most impactful interventions available to the nephrology team. Strategies to preserve RKF include avoiding nephrotoxic agents (such as aminoglycoside antibiotics and non-steroidal anti-inflammatory drugs), maintaining adequate hydration, using biocompatible dialysis solutions, and carefully managing blood pressure.
The clinical take-away is that patients with preserved urine output, even modest amounts, should be treated differently from fully anuric patients. Their prescription does not need to rely entirely on peritoneal clearance, and aggressive target-seeking for peritoneal Kt/V at the expense of RKF would be counterproductive.
The Peritoneal Membrane: Structure, Function, and Vulnerability
How the Membrane Works
The peritoneal membrane achieves solute and fluid transfer through a combination of diffusion, convection, and osmosis. The osmotic gradient that drives fluid removal (ultrafiltration) is created by glucose in the dialysate — typically at concentrations of 1.36%, 2.27%, or 3.86% dextrose. Higher glucose concentrations produce stronger osmotic gradients and greater fluid removal, but also expose the membrane to higher levels of glucose and its metabolic byproducts.
The membrane’s transport properties vary among patients and are classified using the Peritoneal Equilibration Test (PET). Patients are categorized as high, high-average, low-average, or low transporters based on how rapidly solutes move across their membrane. High transporters achieve rapid solute clearance but lose the osmotic gradient quickly, leading to reduced ultrafiltration — a clinically significant problem that can cause volume overload.
Mechanisms of Membrane Deterioration
With prolonged exposure to conventional dialysate, the peritoneal membrane undergoes progressive structural changes that impair its function. These changes were characterized in detail by Davies and colleagues in a landmark histological study published in Kidney International in 2001, which described serial peritoneal biopsies from long-term PD patients.
The principal pathological changes observed include:
- Submesothelial fibrosis: Progressive thickening and scarring of the tissue layer beneath the mesothelial cells lining the peritoneum, leading to reduced membrane permeability and ultrafiltration capacity.
- Vasculopathy: Structural changes to the blood vessels within the peritoneal tissue, impairing the membrane’s transport efficiency.
- Neovascularization: The formation of new blood vessels, which paradoxically increases solute transport (shifting patients toward a high-transporter phenotype) while reducing ultrafiltration — a combination that is clinically challenging to manage.
- Encapsulating peritoneal sclerosis (EPS): A rare but serious complication in which the peritoneal membrane undergoes extensive fibrosis and calcification, encasing the bowel and causing intestinal obstruction. EPS is among the most feared complications of long-term peritoneal dialysis.
The Role of Glucose Degradation Products
The primary driver of peritoneal membrane deterioration is prolonged exposure to glucose degradation products (GDPs) and advanced glycation end products (AGEs) — harmful byproducts generated when dialysate is heat-sterilized during manufacturing. These molecules trigger mesothelial cell injury, stimulate inflammatory pathways, and initiate the fibrotic cascade responsible for membrane damage.
Conventional lactate-buffered peritoneal dialysis solutions have an acidic pH and contain relatively high levels of GDPs. While they are effective and affordable, their biocompatibility is limited. Recognizing this limitation has driven the development of next-generation, biocompatible dialysis solutions.
Biocompatible Solutions: Evidence and Clinical Application
What Makes a Solution “Biocompatible”?
Biocompatible peritoneal dialysis solutions are formulated to reduce the biological harm associated with conventional dialysate. Key features include:
| Feature | Conventional Solution | Biocompatible Solution |
|---|---|---|
| pH | Acidic (5.2–5.5) | Near-physiological (7.0–7.4) |
| GDP content | High | Low (via two-chamber bag technology) |
| Buffer | Lactate | Bicarbonate or bicarbonate/lactate mix |
| Osmotic agent | Glucose (dextrose) | Glucose or icodextrin (glucose polymer) |
| Mesothelial cell toxicity | Higher | Lower |
The balANZ Trial: A Pivotal Study
The most important clinical trial evaluating biocompatible peritoneal dialysis solutions is the balANZ trial, published in The Lancet in 2012 by Johnson and colleagues. This randomized controlled trial compared a neutral-pH, low-GDP bicarbonate/lactate solution against conventional lactate-buffered dialysate over a two-year follow-up period in incident PD patients.
The results were clinically meaningful. Patients receiving the biocompatible solution demonstrated superior preservation of residual kidney function compared to those on conventional dialysate. Additionally, peritonitis rates — a major cause of treatment failure, hospitalization, and mortality in PD patients — were significantly lower in the biocompatible solution group.
These findings strongly support the routine use of biocompatible solutions, particularly in new patients where the benefits of RKF preservation are most pronounced. However, a critical limitation of the balANZ trial and most other studies in this area is their reliance on surrogate outcomes — measures such as urine volume or biomarker levels — rather than hard clinical endpoints like mortality, cardiovascular events, or technique survival. The International Society of Nephrology has specifically called for prospective studies designed and powered to evaluate these harder endpoints, recognizing that the full clinical benefit of biocompatible solutions remains to be definitively established.
Icodextrin: A Special Case
One of the most clinically useful advances in PD solution design is icodextrin — a glucose polymer that exerts its osmotic effect through colloid osmosis rather than crystalloid osmosis. Because it is absorbed much more slowly than glucose, icodextrin maintains an effective osmotic gradient over long dwell periods (eight hours or more), making it particularly valuable for the long overnight dwell in CAPD patients or the long daytime dwell in APD patients.
Evidence from the MIDAS trial and subsequent analyses confirmed that icodextrin provides sustained and reliable ultrafiltration during extended dwells, substantially improving fluid balance in patients who would otherwise accumulate fluid overnight. This makes icodextrin a cornerstone of therapy for patients with ultrafiltration failure or fluid overload — both of which become increasingly common as membrane function deteriorates over time.
Peritonitis Prevention: The Front Line of Membrane Protection
Why Peritonitis Matters So Much
Peritonitis — infection of the peritoneal cavity — is the single most important modifiable risk factor for peritoneal membrane damage. Each episode of peritonitis triggers an acute inflammatory response that causes mesothelial injury and accelerates the fibrotic changes described above. Repeated or severe episodes dramatically increase the risk of membrane failure, technique failure (switching from PD to hemodialysis), and death.
Beyond membrane damage, peritonitis carries direct risks: hospitalization, systemic sepsis, and in severe cases, surgical intervention. Gram-negative peritonitis and fungal peritonitis are associated with particularly poor outcomes and often necessitate permanent PD catheter removal.
Prevention Strategies
The ISN (International Society of Nephrology), through its support of the International Society for Peritoneal Dialysis (ISPD), promotes rigorous peritonitis prevention strategies as a core component of membrane preservation. Key elements include:
- Exit-site care: Standardized protocols for cleaning and dressing the catheter exit site to prevent colonization with skin organisms, particularly Staphylococcus aureus.
- Patient and caregiver training: Comprehensive, structured training in PD technique — including hand hygiene, connection procedures, and recognition of early peritonitis symptoms — is among the most powerful interventions available to reduce peritonitis rates.
- Prophylactic antibiotic use: Nasal screening for Staphylococcus aureus carriage, with topical mupirocin treatment for carriers, significantly reduces exit-site infections and peritonitis.
- Catheter design and insertion technique: Proper catheter placement by trained operators, using evidence-based techniques, reduces early infection risk and mechanical complications.
- Standardized peritonitis surveillance: The ISPD has established clear definitions for peritonitis diagnosis, categorization, and reporting. Adoption of these standardized definitions across centers allows for meaningful benchmarking and quality improvement, and is actively promoted by ISN in its educational and advocacy programs.
ISN’s Role in Advancing Global Standards
The International Society of Nephrology plays a central coordinating role in translating evidence into practice improvements worldwide. Through its educational programs, grant initiatives, and partnerships with regional nephrology societies, ISN works to ensure that high-quality peritoneal dialysis is accessible not only in high-income settings but across the full spectrum of health systems globally.
ISN (International Society of Nephrology) has been particularly active in supporting the dissemination of ISPD position papers on peritonitis management, membrane assessment, and adequacy monitoring — documents that serve as the global reference standard for PD clinical practice. The Society also supports the development of national PD programs in low- and middle-income countries, where PD’s home-based nature and relatively lower infrastructure requirements may offer particular advantages over in-center hemodialysis.
Critically, ISN has identified research gaps that must be addressed to strengthen the evidence base for PD. Chief among these is the need for large, adequately powered prospective trials assessing hard clinical endpoints —
mortality, cardiovascular outcomes, hospitalization, and technique survival — with biocompatible dialysis solutions. The existing evidence, while supportive, has largely relied on surrogate markers that may not fully capture the clinical significance of interventions at the bedside.
Looking Ahead: The Future of Peritoneal Dialysis
Research in peritoneal dialysis is advancing on several fronts. Novel osmotic agents that could provide sustained ultrafiltration with less metabolic burden are under investigation. Better understanding of the molecular mechanisms driving peritoneal fibrosis may yield targeted pharmacological interventions — agents that could interrupt the fibrotic cascade before irreversible membrane damage occurs. Advanced peritoneal equilibration testing and biomarker-based monitoring strategies may enable earlier detection of membrane deterioration, allowing prescription adjustments before clinical consequences emerge.
Digital health technologies, including remote monitoring of PD adequacy parameters and telemedicine support for home-based patients, also hold significant promise for improving outcomes and extending the period during which patients can safely remain on peritoneal dialysis.
Conclusion
Peritoneal dialysis adequacy and membrane preservation are not abstract technical concerns — they are directly and measurably linked to patient survival, quality of life, and the long-term viability of this kidney replacement modality. Achieving a total weekly Kt/V urea of at least 1.7, protecting residual kidney function wherever possible, adopting biocompatible dialysis solutions, rigorously preventing peritonitis, and monitoring membrane health over time are the interconnected strategies that define best-practice peritoneal dialysis care.
The International Society of Nephrology remains committed to advancing these standards through education, evidence synthesis, and advocacy for better-designed clinical research. As the nephrology community continues to refine its understanding of PD biology and therapy optimization, ISN will remain at the forefront of translating science into improved outcomes for patients around the world. For clinicians, policymakers, and patients alike, this work is not peripheral to nephrology — it is central to the mission of preserving and restoring kidney health for all people who need it.